PVAG-14 a Potential New Regimen for Early-Stage Unfavorable Hodgkins

The era of refining combination chemotherapy treatment for Hodgkin's Lymphoma seems never-ending.

Reporting at the annual congress of the European Hematology Association, Dr. Diana Wongso, on behalf of the German Hodgkin's Study Group, explained that a new regimen, PVAG-14 (prednisone, vinblastine, doxorubicin and gemcitabine gave patients better tumor control with a lot less toxicity in patients diagnosed with early-stage unfavorable Hodgkin's, and that it might offer a better alternative to the 2 + 2 chemotherapy normally prescribed for this patient population.

In the study, 40 out of 41 patients achieved complete remission with PVAG-14 therapy. Compare that to the researchers' hopes that as many as half the participants achieve complete remission.

Although a very small trial, the results give researchers hope that this chemotherapy regimen could provide high tumor control with significantly less toxicity. "PVAG-14 might be an effective and less toxic alternative to 2+2 chemotherapy and should be tested in a phase III trial," said Dr. Wongso.

By "2+2 chemotherapy", Dr. Wongso is referring to the tendency among some clinical practice guidelines to recommend two cycles of ABVD and two cycles of BEACOPP for patients with early-stage unfavorable Hodgkin's, a regimen regarded to be unnecessarily toxic.

Median age among patients was 38 years. These results were presented at a medical conference and should be considered preliminary until published in a peer-reviewed journal.

Source: Oncologypractice.com

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap